MedMira Invites Investment Analysts to Conference Call

Mar 07, 2006, 00:00 ET from MedMira Inc.

    HALIFAX, March 7 /PRNewswire-FirstCall/ - MedMira Inc., ("MedMira") (TSX
 Venture: MIR, NASDAQ:   MMIRF) the global market leader in premium rapid
 diagnostic solutions, announced today that it will host a conference call with
 analysts to discuss the company's second quarter financial results and provide
 a corporate update beginning at 9:00 am EST (10:00 am AST) on Wednesday,
 March 8, 2006. MedMira's second quarter financial results were released on
 February 16, 2006 and are available on the MedMira website at
     In order to listen to the conference call, please dial 1-800-814-4861
 toll-free anywhere in Canada or the USA, or 1-416-644-3417 in the Toronto
     A replay of the call will be available until 23:59 pm EST, Thursday,
 March 16, 2006 and may be accessed by dialing 1-877-289-8525 toll-free
 anywhere in Canada or the USA, or 1-416-640-1917 in the Toronto area, and
 entering the pass code 21180349 followed by the number sign anytime after the
 call has ended.
     About MedMira
     MedMira is the leading global manufacturer and marketer of in vitro flow-
 through rapid diagnostic tests. MedMira's tests provide reliable, rapid
 diagnosis in just 3 minutes for the detection of human antibodies in human
 serum, plasma or whole blood for diseases such as HIV and hepatitis C. The
 United States FDA and the SFDA in the People's Republic of China have approved
 MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests, respectively.
     MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used
 in clinical laboratories, hospitals, and clinics where professional
 counselling and patient treatment are immediately available.
     The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter
 (OTC) in pharmacies throughout Hong Kong and Macao Special Administrative
 Regions, in the People's Republic of China. MiraCare(TM) is sold through
 MedMira's distributor network to pharmacies, hospitals and laboratories in the
 European Union.
     MedMira delivers rapid diagnostic solutions to healthcare communities
 around the globe. Its corporate offices and manufacturing facilities are
 located in Halifax, Nova Scotia, Canada with a representative office in
 Guilin, China.
     This news release contains forward-looking statements, which involve risk
 and uncertainties and reflect the company's current expectation regarding
 future events. Actual events could materially differ from those projected
 herein and depend on a number of factors including, but not limited to,
 changing market conditions, successful and timely completion of clinical
 studies, uncertainties related to the regulatory approval process,
 establishment of corporate alliances and other risks detailed from time to
 time in the company quarterly filings.
     The TSX Venture Exchange has not reviewed and does not accept
     responsibility for the adequacy or accuracy of this statement.
     For more information visit MedMira's website at

SOURCE MedMira Inc.